Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) had its target price reduced by stock analysts at Wells Fargo & Company from $25.00 to $23.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has an "overweight" rating on the stock. Wells Fargo & Company's price objective suggests a potential upside of 197.16% from the stock's previous close.
A number of other brokerages have also issued reports on ORIC. BTIG Research reiterated a "buy" rating and issued a $26.00 target price on shares of Oric Pharmaceuticals in a research report on Tuesday. Leerink Partners initiated coverage on Oric Pharmaceuticals in a research note on Monday, October 5th. They set an "outperform" rating and a $26.00 price objective for the company. Citigroup upped their price objective on shares of Oric Pharmaceuticals from $16.00 to $17.00 and gave the company a "buy" rating in a research note on Tuesday. HC Wainwright raised their price objective on shares of Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a "buy" rating in a research note on Monday, August 10th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Oric Pharmaceuticals in a report on Thursday, October 15th. Fourteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Oric Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $21.17.
View Our Latest Stock Analysis on ORIC
Oric Pharmaceuticals Price Performance
Oric Pharmaceuticals stock traded down $0.26 during midday trading on Wednesday, hitting $7.74. 24,839 shares of the company were exchanged, compared to its average volume of 1,707,785. Oric Pharmaceuticals has a fifty-two week low of $7.23 and a fifty-two week high of $14.68. The company's fifty day moving average price is $11.36 and its 200-day moving average price is $10.98. The company has a market cap of $802.25 million, a PE ratio of -5.30 and a beta of 1.23.
Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.05). On average, analysts expect that Oric Pharmaceuticals will post -1.53 EPS for the current fiscal year.
Insider Buying and Selling at Oric Pharmaceuticals
In other news, CFO Dominic Piscitelli sold 14,000 shares of Oric Pharmaceuticals stock in a transaction dated Tuesday, October 20th. The shares were sold at an average price of $13.53, for a total transaction of $189,420.00. Following the sale, the chief financial officer directly owned 69,828 shares in the company, valued at approximately $944,772.84. The trade was a 16.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 105,000 shares of company stock worth $1,432,952. 5.70% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Oric Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of ORIC. WINTON GROUP Ltd acquired a new stake in shares of Oric Pharmaceuticals in the 2nd quarter valued at about $899,000. Defilade Capital Management L.P. acquired a new position in Oric Pharmaceuticals during the 1st quarter worth approximately $10,680,000. Squarepoint Ops LLC acquired a new position in Oric Pharmaceuticals during the 2nd quarter worth approximately $3,729,000. Blue Owl Capital Holdings LP bought a new position in shares of Oric Pharmaceuticals during the 2nd quarter worth approximately $4,332,000. Finally, Bank of America Corp DE bought a new position in shares of Oric Pharmaceuticals during the 2nd quarter worth approximately $11,675,000. 95.05% of the stock is owned by institutional investors and hedge funds.
Oric Pharmaceuticals Company Profile
(
Get Free Report)
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company's drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oric Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oric Pharmaceuticals wasn't on the list.
While Oric Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.